Anastrozole Denk 1MG N30 Tablet

ANASTROZOLE DENK, 1 mg film-coated tablets

ANASTROZOLE DENK composition

Active substance: Each tablet contains 1 mg anastrozole.

Indications

Anastrozole Denk 1 mg is indicated in the following cases: - treatment of hormone receptor-positive breast cancer in women who are postmenopausal; - treatment of hormone receptor-positive, advanced breast cancer in postmenopausal women; - adjuvant treatment of hormone receptor-positive, early invasive breast cancer in postmenopausal women; - adjuvant treatment of hormone receptor-positive, early invasive breast cancer in postmenopausal women who have received adjuvant tamoxifen for more than 2–3 years.

Contraindications

Anastrozole Denk 1 mg is contraindicated in the following cases: ˗ pregnancy or breastfeeding; ˗ hypersensitivity to anastrozole or to any of the other components of this medicinal product.

Use during pregnancy and breastfeeding

There is no experience with the use of anastrozole in pregnant women up to the current period. Animal studies have shown reproductive toxicity. Anastrozole Denk 1 mg is contraindicated during pregnancy. There is no experience regarding the use of anastrozole during breastfeeding up to the current period.

Anastrozole Denk 1 mg is contraindicated during breastfeeding. Fertility The effect of anastrozole on fertility has not been studied. Animal studies have shown reproductive toxicity.

Effect on the ability to drive vehicles and operate other potentially dangerous machinery

The Anastrozole Denk medicinal product does not affect or affects only slightly the ability to drive a vehicle and operate other potentially dangerous machinery. However, cases of asthenia and drowsiness have been reported during the use of anastrozole, and as long as these symptoms persist, caution is required when using a vehicle or other machinery.

ANASTROZOLE DENK dosage and method of use

Posology The recommended dose of Anastrozole Denk 1 mg for adults, including elderly patients, is 1 mg tablet once daily. For women in the postmenopausal period with early invasive breast cancer with hormone receptors positive, the recommended duration of adjuvant endocrine therapy is 5 years. In special patient groups, there is insufficient information regarding the safety and efficacy of Anastrozole Denk 1 mg in pediatrics; therefore, its use in children and adolescents is not recommended. Renal impairment Dose adjustment is not recommended for patients with mild to moderate renal impairment.

Anastrozole Denk 1 mg should be used with caution in patients with severe renal impairment. Hepatic impairment Dose adjustment is not recommended for patients with hepatic impairment. Anastrozole Denk 1 mg should be used with caution in patients with severe hepatic impairment. Method of administration Anastrozole Denk 1 mg is taken orally.

Disposal Any unused medicinal product or waste material should be disposed of in accordance with local requirements.